B+
Bull case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
CRBP
CorbusANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
CRBP has multiple 2026 shots on goal: ASCO monotherapy data for CRB-701, potential mid-2026 registrational-study initiation after FDA alignment, and summer Phase 1b CRB-913 data, while company guidance suggests runway into 2028 [#PR-2026-04-07] [#PR-2026-04-14] [#PR-2026-03-09].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +12.6.
What can break
ASCO 2026 CRB-701 data may fail to show enough durability or subgroup strength to support the emerging registrational narrative [#PR-2026-04-07].
Momentum
74
Value
41
Sentiment
80
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.00 · Bull $18.00 · Bear $5.00Analysis 2026-04-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $35.89
Why
Momentum74 · Δ7d -11.0
Value41 · Δ7d 0.0
Sentiment80 · Δ7d +12.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +12.6.
Contradictions & invalidation
- • ASCO 2026 CRB-701 data may fail to show enough durability or subgroup strength to support the emerging registrational narrative [#PR-2026-04-07].
- • CRB-913 summer 2026 data could disappoint on efficacy, durability, or tolerability despite encouraging early Phase 1a signals [#PR-2026-04-14].
- • This is still a low-coverage, small-cap biotech with binary clinical risk, only moderate evidence quality in the packet, a negative deterministic return prior, and limited proof yet that FDA alignment or early obesity signals will translate into durable value creation.
Catalyst clock
2026-05-29
Updated CRB-701 monotherapy data at ASCO 2026
Lead driver: Sentiment · See AI snapshot
Momentum
74
9% active weight
Current posture
7d trendSoftening
Δ7d
-11.0
Δ21d
+2.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
80
62% active weight
Current posture
7d trendImproving
Δ7d
+12.6
Δ21d
-4.1
Why this grade
Composite grade A. Momentum 74.3 / Value 41.2 / Sentiment 80.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-17. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$202.89M
Beta
2.87
Shares Out
19.34M
P/E (TTM) · Derived
-1.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.05
Rev YoY
-100.0%
EPS YoY
+25.1%
Gross Margin
-
Op Margin
-
Net Debt
-$162.31M
Current Ratio
5.71
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data